Objective
It is well documented that each human cancer has acquired a large number of mutations (50-500), some of which are drivers for tumorigenicity, others of which are indolent passengers. It has also been established that such mutations can be recognized by the patient´s T cells via the presentation of mutated peptides on HLA molecules of a tumor cell. If such immune responses against cancer mutations are generally relevant for cancer development (according to Paul Ehrlich´s hypothesis), one can predict several consequences: 1) The spectrum of mutations found in an established tumor of a patient should be diminished for those that give rise to peptides presented by the HLA molecules of this patient, but not for peptides relevant for other HLA molecules. 2) In HLA-negative tumor cells, the spectrum of mutations (those that occurred after HLA loss) should no longer be dependent on the patient´s HLA molecules. 3) A cancer patient should have T cells against mutations that occurred at an early point in cancer development but that are no longer present in the tumor at the time of diagnosis because of negative selection of such tumor cells by the immune response. The aim of this proposal is to test the hypothesis by studying these three predictions in a large cohort of cancer patients treated at the University Hospital of Tübingen. Clinically relevant human cancer samples from several cancer entities will be tested for mutations by exome and transcriptome sequencing. Those mutations actually presented as HLA ligands will be analyzed by mass spectrometry, and the patient´s T-cell repertoire against mutations will be analyzed. The result of this research should be the confirmation, the rejection, or an amendment of the hypothesis. The outcome will be of decisive influence on the cancer therapy of the future, both for the targeting of cancer pathways using small molecule inhibitors, and for the individualized immunotherapy of cancer by targeting mutations.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics mutation
- medical and health sciences clinical medicine oncology
- natural sciences chemical sciences analytical chemistry mass spectrometry
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
ERC-2013-ADG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Host institution
72074 Tuebingen
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.